OFM
BEAM icon

Omega Fund Management’s Beam Therapeutics BEAM Stock Holding History

Omega Fund Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-302,821
Closed -$8.48M – 17
2020
Q2 		$8.48M Hold
302,821
– – 2.32% 9
2020
Q1 		$5.45M Buy
+302,821
New +$6.58M 2.26% 9

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Omega Fund Management's BEAM Position: Q3 2020 in Review

Omega Fund Management sold out of Beam Therapeutics (BEAM) in Q3 2020, closing a stake of 302,821 shares — an estimated $8.48M sold.

Omega Fund Management first reported a position in BEAM in Q1 2020 and held it in 2 quarters. The position peaked at $8.48M in Q2 2020. 85 funds tracked by Wall St. Rank hold BEAM as of Q3 2020.

  • Omega Fund Management reported no remaining Beam Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Omega Fund Management sold 302,821 Beam Therapeutics shares in Q3 2020, an estimated $8.48M.
  • Omega Fund Management first reported a position in Beam Therapeutics in Q1 2020 and held it in 2 quarters.
  • Omega Fund Management's Beam Therapeutics position peaked at $8.48M in Q2 2020.
  • 85 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2020.

Based on Omega Fund Management's 13F filing for Q3 2020, filed 16 Nov 2020.